Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4020810 | 1.00 | CA1 (0.50) | CA1CA2CA7CA9CA4 | |
| SCHEMBL4020804 | 1.00 | CA1 (0.50) | CA1CA2CA7CA9CA4 | |
| SCHEMBL3648172 | 0.88 | CA1 (0.40) | CA1CA2CA7CA9CA4 | |
| SCHEMBL3648169 | 0.88 | CA1 (0.40) | CA1CA2CA7CA9CA4 | |
| SCHEMBL7429844 | 0.85 | AR (0.55) | CA1CA2CA7CA9CA4 | |
| SCHEMBL11686413 | 0.85 | AR (0.55) | CA1CA2CA7CA9CA4 | |
| SCHEMBL28581384 | 0.85 | ALDH1A1 (0.43) | CA1CA2CA7CA9CA4 | |
| SCHEMBL13841806 | 0.85 | ALDH1A1 (0.43) | CA1CA2CA7CA9CA4 | |
| SCHEMBL28581383 | 0.85 | ALDH1A1 (0.43) | CA1CA2CA7CA9CA4 | |
| SCHEMBL7925816 | 0.85 | GAA (0.49) | CA2CA7CA9ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813987-B1 | SULFONIC-ESTER-CONTAINING COMPOSITION FOR FORMATION OF ANTIREFLECTION FILM FOR LITHOGRAPHY | NISSAN CHEMICAL IND LTD (JP) | 2011-08-24 | — | — | EP | claimed |
| US-12630544-B2 | Compound, α-synuclein aggregate binder, and use thereof | National Institutes for Quantum Science and Technology (JP) | 2026-05-19 | — | — | US | disclosed |
| CN-120092035-A | Cationically curable composition | 日产化学株式会社 | 2025-06-03 | — | — | CN | disclosed |
| US-20230399323-A1 | NOVEL COMPOUND, a-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-14 | — | — | US | disclosed |
| EP-4206200-A1 | NOVEL COMPOUND, ALPHA-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF | National Institutes for Quantum Science and Technology (JP) | 2023-07-05 | — | — | EP | disclosed |
| CN-115989029-A | Novel compound, alpha synuclein aggregate binding agent, and use thereof | 国立研究开发法人量子科学技术研究开发机构 | 2023-04-18 | — | — | CN | disclosed |
| WO-2022045093-A1 | NOVEL COMPOUND, α-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF | 国立研究開発法人量子科学技術研究開発機構 | 2022-03-03 | — | — | WO | disclosed |
| WO-2012136305-A1 | PROCESS FOR IMPROVING THE ELECTRICAL PARAMETERS IN CAPACITORS COMPRISING PEDOT/PSS AS SOLID ELECTROLYTE, BY MEANS OF ADDITIVES | HERAEUS PRECIOUS METALS GMBH & CO. KG (DE) | 2012-10-11 | — | — | WO | disclosed |
| EP-1813987-B1 | SULFONIC-ESTER-CONTAINING COMPOSITION FOR FORMATION OF ANTIREFLECTION FILM FOR LITHOGRAPHY | NISSAN CHEMICAL IND LTD (JP) | 2011-08-24 | — | — | EP | disclosed |
| US-7615331-B2 | Photosensitive resin composition, production method of cured relief pattern using the same and semiconductor device | FUJIFILM CORPORATION (JP) | 2009-11-10 | — | — | US | disclosed |
| US-5242943-A | Administering as beta adrenoceptor blocking agents | Louis, William J. (AU) | 1993-09-07 | — | — | US | disclosed |
| US-5187293-A | Blood platelet activating factor inhibitors | HOFFMANN-LA ROCHE INC. (US) | 1993-02-16 | — | — | US | disclosed |
| US-5051445-A | Cardiovascular disorders such as antiarrhythmia or cardiotonic agents, adrenergic blocking agents | Louis, William J. (AU) | 1991-09-24 | — | — | US | disclosed |
| EP-0177515-B1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Louis, William John (AU) | 1989-05-31 | — | — | EP | disclosed |
| EP-0147768-B1 | GLYCERIN DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1989-02-08 | — | — | EP | disclosed |
| US-4731373-A | BLOOD PLATELET ACTIVATING FACTOR | HOFFMAN-LA ROCHE INC. (US) | 1988-03-15 | — | — | US | disclosed |
| EP-0177515-A4 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | SANDOZ LTD (CH) | 1986-09-23 | — | — | EP | disclosed |
| EP-0177515-A1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | SANDOZ LTD (CH) | 1986-04-16 | — | — | EP | disclosed |
| WO-1985004403-A1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANDOZ LTD. (CH) | 1985-10-10 | — | — | WO | disclosed |
| US-4182911-A | BETA-ADRENERGIC BLOCKING AGENTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399323-A1 | NOVEL COMPOUND, a-SYNUCLEIN AGGREGATE BINDER, AND USE THEREOF | SNCA, PARK7, ATXN2L | CA1 3364/4885CA2 3080/4885CA7 4118/4885 |
| US-12630544-B2 | Compound, α-synuclein aggregate binder, and use thereof | SNCA, PARK7, MAPT | CA1 3244/4885CA2 3217/4885CA7 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.